BioWorld MedTech

Nov. 9, 2016

In Asia, regulatory harmonization in med tech clashes with the reality on the ground level

SINGAPORE – Harmonization of regulations throughout the Asia Pacific region has been an ongoing goal in the past 20 years, but regulators across the region are now coming to accept that this particular goal may never be achieved. Read More

More bad news for Valeantin form of warning letter

FDA gives green light to Seaspine's Mariner fixation system ahead of its earnings report

Ng Biotech and Atomo Diagnostics unveil rapid next-gen blood-based hCG diagnostic

Product briefs

Daily M&A

Other news to note

Appointments & advancements

Today's news in brief

BioWorld

BioWorld briefs for April 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 4, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.

Checkpoint inhibitor journey traces Chinese firms’ path to global revenue

BioWorld

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune...